Development of AhR inhibitors for oral antiviral therapy for COVID-19 patients (Q3988868): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed an Item: Edited by the infer coords bot - inferring coordiantes from postal codes)
(‎Changed label, description and/or aliases in en: Adding English translations)
label / enlabel / en
 
Development of AhR inhibitors for oral antiviral therapy for COVID-19 patients

Revision as of 19:48, 13 December 2021

Project Q3988868 in Netherlands
Language Label Description Also known as
English
Development of AhR inhibitors for oral antiviral therapy for COVID-19 patients
Project Q3988868 in Netherlands

    Statements

    399,362.0 Euro
    0 references
    1,055,117.569 Euro
    0 references
    37.85 percent
    0 references
    1 June 2020
    0 references
    1 June 2021
    0 references
    Hercules Pharmaceuticals
    0 references
    0 references

    53°14'32.42"N, 6°31'47.86"E
    0 references

    52°10'7.79"N, 4°28'2.14"E
    0 references
    2333BD
    0 references
    9747AT
    0 references

    Identifiers

    OP-2014-2023-Noord-OPSNN0302
    0 references